LNAI Key Statistics, Chart & Performance
The current stock price of LNAI is 0.7804 USD. In the past month the price decreased by -11.49%.
LNAI Technical Analysis
ChartMill assigns a technical rating of 1 / 10 to LNAI.
LNAI Financial Highlights
Over the last trailing twelve months LNAI reported a non-GAAP Earnings per Share(EPS) of -7.51. The EPS decreased by -72.28% compared to the year before.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PM (TTM) | N/A | ||
| ROA | -1881.62% | ||
| ROE | N/A | ||
| Debt/Equity | N/A |
LNAI Forecast & Estimates
LNAI Ownership
About LNAI
Company Profile
Lunai Bioworks, Inc. is a pre-clinical stage biotechnology company, which engages in the development of genetically modified cellular and immune-therapy technologies used for the treatment of infectious diseases and cancer. The company is headquartered in Los Angeles, California and currently employs 29 full-time employees. The company went IPO on 2014-11-18. The company is engaged in harnessing advanced computational biology and AI/machine learning to accelerate drug discovery, diagnostics and strengthen biosecurity capabilities. Its segments include RENB, BioSymetrics and RENC. The RENB segment is engaged in developing new immunotherapies to combat cancer. BioSymetrics is engaged in integrating multimodal data sources, including genomics, imaging, electronic health records, and other real-world evidence, to advance biomarker discovery, therapeutic development, and precision medicine. RENC is developing a predicative artificial intelligence-based diagnostic methodology for the use of earlier cancer detection. From high-resolution phenotyping to predictive disease modeling, the Company is pioneering a new era of precision diagnostics-where early detection, patient stratification, and therapeutic targeting converge into a single, adaptive platform.
Company Info
LUNAI BIOWORKS INC
2080 Century Park East, Suite 906
Los Angeles CALIFORNIA US
Employees: 29
Phone: 14539179840
LUNAI BIOWORKS INC / LNAI FAQ
What does LNAI do?
Lunai Bioworks, Inc. is a pre-clinical stage biotechnology company, which engages in the development of genetically modified cellular and immune-therapy technologies used for the treatment of infectious diseases and cancer. The company is headquartered in Los Angeles, California and currently employs 29 full-time employees. The company went IPO on 2014-11-18. The company is engaged in harnessing advanced computational biology and AI/machine learning to accelerate drug discovery, diagnostics and strengthen biosecurity capabilities. Its segments include RENB, BioSymetrics and RENC. The RENB segment is engaged in developing new immunotherapies to combat cancer. BioSymetrics is engaged in integrating multimodal data sources, including genomics, imaging, electronic health records, and other real-world evidence, to advance biomarker discovery, therapeutic development, and precision medicine. RENC is developing a predicative artificial intelligence-based diagnostic methodology for the use of earlier cancer detection. From high-resolution phenotyping to predictive disease modeling, the Company is pioneering a new era of precision diagnostics-where early detection, patient stratification, and therapeutic targeting converge into a single, adaptive platform.
What is the current price of LNAI stock?
The current stock price of LNAI is 0.7804 USD. The price decreased by -7.11% in the last trading session.
What is the dividend status of LUNAI BIOWORKS INC?
LNAI does not pay a dividend.
What is the ChartMill rating of LUNAI BIOWORKS INC stock?
LNAI has a ChartMill Technical rating of 1 out of 10 and a ChartMill Fundamental rating of 0 out of 10.
How is the valuation of LUNAI BIOWORKS INC (LNAI) based on its PE ratio?
LUNAI BIOWORKS INC (LNAI) does not have a PE ratio as the earnings reported over the last twelve months were negative (-7.51).
What is the employee count for LNAI stock?
LUNAI BIOWORKS INC (LNAI) currently has 29 employees.
What is the market capitalization of LNAI stock?
LUNAI BIOWORKS INC (LNAI) has a market capitalization of 18.28M USD. This makes LNAI a Nano Cap stock.